By utilizing both 2D and 3D epithelial models alongside patient-informed prioritization, we provide proof-of-concept that repurposed agents can be systematically assessed for feasibility, efficacy, and translational potential in endometriosis, highlighting both the promise of novel molecular candidates such as ROR1 and the broader value of repurposing to accelerate effective, well-tolerated therapies. Here, ROR1 is linked to endometriosis.